Patient Selection for CAR T-Cell Therapy at First Relapse

Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including disease burden and the role of holding and bridging therapy, age and fitness, kidney function, and caregiver availability. They discuss patient-centered decision making, insurance and access barriers, and comorbidities such as neurologic and cardiac conditions. One panelist describes optimizing cardiovascular health and involving neurology colleagues before CAR T-cell therapy.